| Teddy Gonzalez, MD | |
|
11546 Ryan Manor Dr, Richmond, TX 77406-3994 | |
| (713) 670-6261 | |
| Not Available |
| Full Name | Teddy Gonzalez |
|---|---|
| Gender | Male |
| Speciality | General Practice |
| Location | 11546 Ryan Manor Dr, Richmond, Texas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1801134101 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | 0911090082 (ZZ) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Teddy Gonzalez, MD 11546 Ryan Manor Dr, Richmond, TX 77406-3994 Ph: () - | Teddy Gonzalez, MD 11546 Ryan Manor Dr, Richmond, TX 77406-3994 Ph: (713) 670-6261 |
News Archive
Scientists have developed a new test that can help identify people who are likely to develop hepatocellular carcinoma (HCC), the most common form of liver cancer. The approach uses a simple blood test to check for the patient's previous exposure to certain viruses.
The plan, advanced by Rep. Allyson Schwartz, D-Pa., would prevent a 27.4 percent cut in Medicare physician payments from kicking in Jan. 1, phase out the current outdated formula and transition to a new one. Though some physician groups are lining up behind her approach, the American Medical Association has not yet "on board."
The U.S. Food and Drug Administration today approved Jevtana (cabazitaxel), a chemotherapy drug used in combination with the steroid prednisone to treat men with prostate cancer. Jevtana is the first treatment for advanced, hormone-refractory, prostate cancer that has worsened during or after treatment with docetaxel, a commonly used drug for advanced prostate cancer.
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders, today reported that it presented data at the NCDEU 50th Anniversary Meeting showing that its novel mechanism compound GLYX-13 appeared safe in a Phase I trial. GLYX-13 is a glycine site functional partial agonist selective modulator of the NMDA receptor that is being developed initially for use in depression as adjunctive therapy.
› Verified 7 days ago
Joanna Rodriguez Quinquilla, MD General Practice Medicare: Accepting Medicare Assignments Practice Location: 400 Austin St, Richmond, TX 77469 Phone: 281-342-4530 Fax: 281-341-2920 | |
Dr. James S Bromberg, M.D. General Practice Medicare: Not Enrolled in Medicare Practice Location: 3703 Aspenwood Dr, Richmond, TX 77469 Phone: 832-595-9930 | |
Dr. Wena Chiranand, M.D. General Practice Medicare: Not Enrolled in Medicare Practice Location: 2100 Preston St, Richmond, TX 77469 Phone: 281-344-4607 Fax: 281-344-4606 | |
Dr. Kiran R Parikh, M.D. General Practice Medicare: Not Enrolled in Medicare Practice Location: 2100 Preston St, Richmond, TX 77469 Phone: 281-344-4608 Fax: 281-344-4606 | |
Mr. Nanthaphonge Chiranand, MD General Practice Medicare: Not Enrolled in Medicare Practice Location: 2100 Preston St, Richmond, TX 77469 Phone: 281-344-4223 Fax: 281-344-4606 | |
Dr. Thomas Herbert Chapman Jr., MD General Practice Medicare: Not Enrolled in Medicare Practice Location: 1615 Rambling Stone Dr, Richmond, TX 77406 Phone: 281-342-8511 |